180 related articles for article (PubMed ID: 22681919)
1. [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
Li L; Zhong W; Liao M; Chen L; Han B; Guan Z; Yu S; Liu X; Wu Y; Jiang G; Xu J; Chen J; Tao M; Luo R; Li W; Xu N; Zhao X; Wang M
Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):332-9. PubMed ID: 22681919
[TBL] [Abstract][Full Text] [Related]
2. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Hirsch FR; Sequist LV; Gore I; Mooradian M; Simon G; Croft EF; DeVincenzo D; Munley J; Stein D; Freivogel K; Sifakis F; Bunn PA
Cancer; 2018 Jun; 124(11):2407-2414. PubMed ID: 29579334
[TBL] [Abstract][Full Text] [Related]
5. The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Gottschling S; Herpel E; Eberhardt WE; Heigener DF; Fischer JR; Köhne CH; Kortsik C; Kuhnt T; Muley T; Meister M; Bischoff HG; Klein P; Moldenhauer I; Schnabel PA; Thomas M; Penzel R
Lung Cancer; 2012 Jul; 77(1):183-91. PubMed ID: 22483783
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
9. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S
J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866
[TBL] [Abstract][Full Text] [Related]
12. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L; Li JR
Zhonghua Nei Ke Za Zhi; 2008 Apr; 47(4):291-5. PubMed ID: 18843952
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Huang H; Zhang Y; Zhao HY; Wang ZQ; Xu F; Xu GC; Zhang L; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):148-51. PubMed ID: 19538895
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Cappuzzo F; Morabito A; Normanno N; Bidoli P; Del Conte A; Giannetta L; Montanino A; Mazzoni F; Buosi R; Burgio MA; Cerea G; Chiari R; Cortinovis D; Finocchiaro G; Foltran L; Migliorino MR; Tiseo M; Ferrari S; De Marinis F
Lung Cancer; 2016 Sep; 99():31-7. PubMed ID: 27565910
[TBL] [Abstract][Full Text] [Related]
17. Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
Razis E; Skarlos D; Briasoulis E; Dimopoulos M; Fountzilas G; Lambropoulos S; Rigatos S; Kopterides P; Efstathiou H; Tzamakou E; Bakoyannis C; Pectasides D; Makatsoris T; Varthalitis G; Papadopoulos S; Kosmidis P
Anticancer Drugs; 2005 Feb; 16(2):191-8. PubMed ID: 15655417
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Zhang Y; Zhang L; Xu F; Wang ZQ; Zhao HY; Guan ZZ; Xu GC; Pan ZK
Ai Zheng; 2006 Dec; 25(12):1561-4. PubMed ID: 17166387
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
